ETTLINGEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today has launchedPhenoRiskPACS™ RuO, a research-use-only NMR test for molecular phenomics research on ‘Long COVID’ patients’ blood samples, using a multiplexed combination of biomarkers discovered at the Australian National Phenome Center (ANPC) at Murdoch University, under Director Jeremy Nicholson. ThePhenoRiskPACS™ RuO对于早期危险因素，纵向恢复监测以及心血管疾病，II型糖尿病，肾功能障碍和炎症的潜在次要器官损害的研究，测试是有望进行的。它由Avance™IVDRNMR spectroscopy system that is testing several biological mechanisms of action simultaneously in a 20-minute blood-test from SARS-CoV-2 acute infection survivors who suffer long-term sequelae, termed either Post-Acute COVID Syndrome (PACS), or commonly known as ‘Long COVID’ syndrome.
This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20220706005075/en/
ANPC Molecular Phenomics NMR Lab (Photo: Business Wire)
Recent publicationshave demonstrated that NMR is playing a pivotal role in measuring COVID-19 progression based on phenomic molecular signatures, and it is also providing new insights into various PACS mechanisms of action, as well as into Long COVID clinical management and treatment options. ThePhenoRiskPACS™ RuO测试表征SARS-COV-2病理生物学的代谢和蛋白质组学生物标志物，即使在无症状的急性共同病例中，也可以在多种长时间的共同功能障碍中实现多器官风险评估，恢复和治疗性研究。
This new NMR test has the potential to quantitatively discriminate PACS patients from healthy or fully recovered individuals by studying COVID-triggeredpheno-conversion，被定义为急性感染后人血浆样品中分子特征的瞬时或持续的全身变化。随后的pheno-reversionof metabolic signatures detected byPhenoRiskPACS™ RuOmay indicate PACS recovery.
In addition to metabolism analytes,PhenoRiskPACS™ RuO量化composite signals for groups of glycoproteins and phospholipids, which can indicate inflammation and cardiovascular disease risk, as well as a new NMR biomarker called超分子磷脂复合材料（SPC）。这些标记显示了COVID-19与对照组的极好歧视，而GLYC/SPC比率已被认为是长期共同的有用分子标记，这可能会大大增加当前的临床和治疗研究。
Dr. Oscar Millet, leader of the Precision Medicine and Metabolism group atCIC Biogunein Bilbao, Spain, commented: “PhenoRiskPACS™ RuOis an automated, easy to use and standardized approach to investigate the complex metabolomic signatures induced by SARS-CoV-2. It enables clinical research on the screening and monitoring of long-term sequelae after acute COVID-19, in patients with Long COVID syndrome, and even in asymptomatic subjects – a breakthrough in understanding PACS.”
Dr. Iris Mangelschots, President of Bruker BioSpin’s Applied, Industrial and Clinical Division, commented: “We are very excited to provide this multi-organ PACS risk screen to the clinical and pharmaceutical research community, after the preliminary validation by our partners in the International COVID-19 Research Network. We believe thatPhenoRiskPACS™ RuOcould make a significant contribution in research to combat the effects of Long COVID.”
PhenoRisk PACS1.0™ RuO扩展Bruker根据公司的临床研究提供的产品Avance™IVDRNMR platform, which already provides lipoprotein profiles (B.I.LISA) and quantification of small molecules in plasma and urine (B.I.QuantPS2.0,B.I.QuantUR1.1).
About Bruker Corporation(Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit:www.energie2point0.com.
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20220706005075/en/
Investor Contact:
Justin Ward
投资者关系与企业发展高级总监
t：+1（978）663-3660，分机。1479年
E:Investor.relations@bruker.com
Media Contact:
Thorsten Thiel，博士
Vice President of Group Marketing
Bruker Biospin
t：+49（721）5161–6500
E:pr@bruker.com
Source: Bruker Corporation